Ventilator Induced Diaphragm Dysfunction
Conditions
Keywords
Diaphragm atrophy, VIDD, Weaning failure
Brief summary
A randomized clinical trial to investigate the use of the temporary Diaphragm Pacing Therapy System (DPTS) to rehabilitate the diaphragm in mechanically ventilated patients who have failed at least two weaning attempts. The goal is to strengthen and rehabilitate the diaphragm to liberate the patient more quickly from mechanical ventilation.
Detailed description
Mechanical ventilation (MV) is a life saving technology but can also cause damage to the lungs and diaphragm such as ventricular induced diaphragmatic dysfunction (VIDD). Research has shown that after being on mandatory MV and sedated the diaphragm begins to atrophy within as short as 18 hours. The Lungpacer Diaphragm Pacing Therapy System (DPTS) is a temporary therapy that consists of the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) and the Lungpacer Control Unit system. The LIVE Catheter is a proprietary central venous catheter that incorporates pacing electrodes in strategic areas that align with the left and right phrenic nerves. The LIVE Catheter can also be used for fluid delivery like any other central venous catheter. The randomized clinical trial will investigate the safety, effectiveness and performance of the Lungpacer DPTS. By stimulating the diaphragm through daily therapy sessions, with the intention of exercising and rehabilitating the diaphragm muscle so the patient may be able to be more quickly liberated from MV. The patient population includes those who have been mechanically ventilated for greater than or equal to 96 hours (4days), have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during the latest spontaneous breathing trial. Patients must have resolution of the initial indication for placement on mechanical ventilation before entering the trial.
Interventions
DEVICEDiaphragmatic Pacing Therapy DPTS
Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.
Sponsors
Syntactx
Lungpacer Medical Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The ultrasound core lab reviewers will be blinded to study allocation groups
Intervention model description
1:1 randomization of treatment and control group
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 18 years of age or older * have been mechanically ventilated for \> or = to 96 hours (4 days), and * have satisfied the Readiness-to-Wean criteria and * have failed at least two VLTs, one of which is the study specific VLT.
Exclusion criteria
* currently on extracorporeal membrane oxygenation (ECMO); * weaning failure due to hypervolemia; * medical history or known anatomy that prevents insertion of the LIVE Catheter into the left subclavian vein; * currently being treated with neuromuscular blockade; * clinically overt congestive heart failure that is preventing weaning; * pre-existing neuromuscular diseases that could affect the respiratory muscles; * pre-existing severe chronic pulmonary fibrosis; * pleural effusions occupying greater than one third of the pleural space on either side; * BMI \> or = 40; * known or suspected phrenic nerve paralysis; * any electrical device (implanted or external) that may be prone to interaction with or interference from the Lungpacer DPTS including neurological pacing/stimulator devices, cardiac pacemakers and defibrillators; * prior bacteremia reported within the last 48 hours; * current hemodynamic instability, sepsis or septic shock; * terminally ill with 6 months or less life expectancy or not committed to full care; * known or suspected to be pregnant or lactating; and * currently being treated in another clinical trial studying an experimental treatment that could affect the study primary outcome.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion successfully weaned by 30 days for subjects randomized to Treatment (Lungpacer DPTS) as compared to subjects randomized to Control. | Patients will be allowed to stay in the study for up to 30 (+2 days of follow up for adverse events) days if not removed from mechanical ventilation sooner | Successfully weaned is defined as passing the protocol-specific Ventilator Liberation Trial (VLT), or removed from MV, and not reintubated (subjects with an oral or nasal, endotracheal tube) or returned to MV (subjects with a tracheostomy) within 48 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in diaphragmatic thickening fraction on diaphragm ultrasound | to successful weaning or on day 30 which ever comes first. | Evaluate difference in changes in diaphragmatic thickening fraction between study allocation groups from randomization to successful weaning or on day 30 whichever comes first; |
| Changes in MIP | to successful weaning, or on day 30, whichever comes first. | Change in MIP from randomization to last available measure; Change in MIP over time from randomization (baseline). |
| Change in MIP | to successful weaning, or on day 30 whichever comes first. | Rate of MIP change per day from randomization (baseline) to last available measure; |
| Changes in RSBI | to successful weaning, or on day 30, whichever comes first | Change in RSBI from randomization (baseline) to last available measure; Change in RSBI over time from randomization (baseline); |
| Change in RSBI | to successful weaning, or on day 30, whichever comes first | Rate of RSBI change per day from randomization (baseline) to last available measure; |
| Mortality | on day 30 | 30-day mortality |
| Days on mechanical ventilation | from randomization to 30 days | Days on mechanical ventilation from randomization to removal from MV associated with successful weaning or Day 30, whichever comes first |
Other
| Measure | Time frame | Description |
|---|---|---|
| Ventilator settings | from randomization to 30 days | Pressure Support daily, to last available measure |
| Number of ICU admissions and discharges through D30 for both groups | from randomization to 30 days | ICU admissions and discharges to day 30 |
| Number of hospital admissions and discharges through D30 for both groups | from randomization to 30 days | Hospital admissions and discharges to day 30. |
| Tracheostomy | from randomization to 30 days | Proportion of subjects tracheotomized from randomization to study exit |
| Weaning from and re-installation of Mechanical Ventilation in both groups | from randomization to 30 days | Cessations and re-instatements of mechanical ventilation to Day 30 or Study Exit |
Countries
France, Germany
Outcome results
None listed